Blockchain Registration Transaction Record

GeoVax CEO to Present Pipeline at ROTH Healthcare Conference

GeoVax Labs CEO David Dodd to present vaccine & cancer therapy pipeline at ROTH Healthcare Conference. Features COVID-19, Mpox vaccines & Gedeptin cancer treatment in Phase 2 trials.

This development matters because GeoVax is advancing multiple vaccine and immunotherapy candidates that address critical public health needs, including next-generation COVID-19 vaccines for immunocompromised patients, Mpox/smallpox preparedness vaccines, and innovative cancer therapies. The company's participation in a major investor conference signals important progress in their clinical programs and potential near-term catalysts. For patients, GeoVax's pipeline represents hope for more effective vaccines and cancer treatments, particularly for vulnerable populations who don't respond well to current options. For investors and the healthcare sector, successful development of these candidates could address significant market gaps while contributing to global health security against infectious disease threats and advancing oncology treatment options.